论文部分内容阅读
应用自行构建的包含HIV复合表位重组DNA疫苗(pCCMp24)和重组减毒天坛株痘苗病毒(rddVTT-CCMp24),通过小鼠实验开展免疫原性研究.采用肌肉注射方式于第0和21天分别进行初次(prime)和加强(boost)免疫.根据既定的免疫程序,在加强免疫后10天,通过检测外周血中HIV特异性抗体IgG,IL-2和IL-4水平,分析针对HIV表位肽的淋巴细胞的增殖能力及CD4+/CD8+细胞的比例,监测淋巴细胞分泌IFN-γ的水平,综合评价疫苗的免疫原性.结果显示,pCCMp24,rddVTT-CCMp24单独免疫及pCCMp24/rddVTT-CCMp24prime-boost联合免疫策略均可诱导体液和细胞免疫应答.而且相对于重组DNA单独免疫,pCCMp24/rddVTT-CCMp24联合免疫可诱导较多的CD8+T细胞及IFN-γ分泌细胞产生.而且联合免疫策略也可诱导针对HIV表位肽的细胞免疫记忆的产生.综上表明,rDNA-rddVTT-CCMp24prime-boost免疫策略倾向于诱导较强的细胞免疫应答,尤其是IFN-γ反应,为下一步研究奠定了基础.
The immunogenicity of the vaccinia virus (rddVTT-CCMp24) containing the HIV complex epitope recombinant DNA vaccine (pCCMp24) and the recombinant attenuated Tiantan and the vaccinia virus (rddVTT-CCMp24) was studied by using mouse intraperitoneal injection on day 0 and 21 respectively Immunization was performed prime and boost.According to the established immunization schedule, the levels of IgG specific for IL-2 and IL-4 in peripheral blood were analyzed 10 days after booster immunization against HIV epitopes The results showed that the immunogenicity of pCCMp24, rddVTT-CCMp24 and pCCMp24 / rddVTT-CCMp24prime- boost combined immunization strategy could induce both humoral and cellular immune responses.Compared with recombinant DNA alone, pCCMp24 / rddVTT-CCMp24 co-immunization induced more CD8 + T cells and IFN-γ-secreting cells, and combined immunization strategy Can induce the production of cellular immune memory against HIV epitope peptide.In summary, rDNA-rddVTT-CCMp24prime-boost immunization strategy tends to induce a strong cellular immune response, especially the IFN-γ response, for the next Research laid the foundation.